Durvalumab plus novel agents in non-small cell lung cancer-a new COAST on the horizon?
Transl Lung Cancer Res
.
2022 Apr;11(4):697-701.
doi: 10.21037/tlcr-21-1002.
Authors
Wolfram C M Dempke
1
2
,
Klaus Fenchel
3
,
Susanne Reuther
2
,
Michael F Murphy
1
Affiliations
1
Worldwide Clinical Trials, Research Triangle Park, North Carolina, USA.
2
Department of Haematology and Oncology, University Medical School Munich, Munich, Germany.
3
Medical Oncology Clinic, Saalfeld, Germany.
PMID:
35529785
PMCID:
PMC9073750
DOI:
10.21037/tlcr-21-1002
No abstract available
Publication types
Editorial